NO319895B1 - Fremgangsmate for fremstilling av spraytorket rhEPO, samt torr rhEPO fremsatt i henhold til denne metoden og sammensetning derav. - Google Patents

Fremgangsmate for fremstilling av spraytorket rhEPO, samt torr rhEPO fremsatt i henhold til denne metoden og sammensetning derav. Download PDF

Info

Publication number: NO319895B1
Authority: NO; Norway
Prior art keywords: rhepo; spray; dried; drying; solution
Prior art date: 1994-12-16

Application number

NO19972725A

Other languages

English (en)

Norwegian (no)

Other versions

NO972725D0 (no

NO972725L (no

Inventor

Deepak B Mehta

Diane Corbo

Khursid Iqbal

Original Assignee

Ortho Pharma Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-12-16

Filing date

1997-06-13

Publication date

2005-09-26

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23407689&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO319895(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1997-06-13 Application filed by Ortho Pharma Corp filed Critical Ortho Pharma Corp

1997-06-13 Publication of NO972725D0 publication Critical patent/NO972725D0/no

1997-08-06 Publication of NO972725L publication Critical patent/NO972725L/no

2005-09-26 Publication of NO319895B1 publication Critical patent/NO319895B1/no

Links

238000000034 method Methods 0.000 title claims description 34
239000000203 mixture Substances 0.000 title claims description 25
238000004519 manufacturing process Methods 0.000 title claims description 8
238000001035 drying Methods 0.000 claims description 31
239000000243 solution Substances 0.000 claims description 24
238000009472 formulation Methods 0.000 claims description 18
239000007921 spray Substances 0.000 claims description 17
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 16
239000007864 aqueous solution Substances 0.000 claims description 16
239000004471 Glycine Substances 0.000 claims description 8
238000001262 western blot Methods 0.000 claims description 8
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 7
229930195725 Mannitol Natural products 0.000 claims description 7
239000000594 mannitol Substances 0.000 claims description 7
235000010355 mannitol Nutrition 0.000 claims description 7
238000000889 atomisation Methods 0.000 claims description 4
239000002245 particle Substances 0.000 claims description 3
150000003839 salts Chemical class 0.000 claims description 3
239000004094 surface-active agent Substances 0.000 claims description 3
239000000654 additive Substances 0.000 claims description 2
238000001694 spray drying Methods 0.000 description 21
102000004169 proteins and genes Human genes 0.000 description 14
108090000623 proteins and genes Proteins 0.000 description 14
239000000546 pharmaceutical excipient Substances 0.000 description 11
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 11
239000000843 powder Substances 0.000 description 11
238000002360 preparation method Methods 0.000 description 11
239000007787 solid Substances 0.000 description 10
238000004108 freeze drying Methods 0.000 description 9
239000008215 water for injection Substances 0.000 description 9
102000003951 Erythropoietin Human genes 0.000 description 8
108090000394 Erythropoietin Proteins 0.000 description 8
238000000502 dialysis Methods 0.000 description 8
229940105423 erythropoietin Drugs 0.000 description 8
230000004071 biological effect Effects 0.000 description 6
238000003127 radioimmunoassay Methods 0.000 description 6
239000003814 drug Substances 0.000 description 5
230000001225 therapeutic effect Effects 0.000 description 5
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
229940079593 drug Drugs 0.000 description 4
238000012360 testing method Methods 0.000 description 4
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
239000000020 Nitrocellulose Substances 0.000 description 3
241000283973 Oryctolagus cuniculus Species 0.000 description 3
239000007979 citrate buffer Substances 0.000 description 3
150000001860 citric acid derivatives Chemical class 0.000 description 3
238000012377 drug delivery Methods 0.000 description 3
238000001704 evaporation Methods 0.000 description 3
230000008020 evaporation Effects 0.000 description 3
239000012527 feed solution Substances 0.000 description 3
239000012634 fragment Substances 0.000 description 3
239000000463 material Substances 0.000 description 3
239000012528 membrane Substances 0.000 description 3
229920001220 nitrocellulos Polymers 0.000 description 3
229920001184 polypeptide Polymers 0.000 description 3
229920000136 polysorbate Polymers 0.000 description 3
102000004196 processed proteins & peptides Human genes 0.000 description 3
108090000765 processed proteins & peptides Proteins 0.000 description 3
239000000523 sample Substances 0.000 description 3
239000011343 solid material Substances 0.000 description 3
238000012430 stability testing Methods 0.000 description 3
239000000126 substance Substances 0.000 description 3
241000283707 Capra Species 0.000 description 2
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
102000003886 Glycoproteins Human genes 0.000 description 2
108090000288 Glycoproteins Proteins 0.000 description 2
101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
239000012298 atmosphere Substances 0.000 description 2
238000004166 bioassay Methods 0.000 description 2
239000000872 buffer Substances 0.000 description 2
239000004067 bulking agent Substances 0.000 description 2
125000000837 carbohydrate group Chemical group 0.000 description 2
238000005352 clarification Methods 0.000 description 2
238000013270 controlled release Methods 0.000 description 2
210000003743 erythrocyte Anatomy 0.000 description 2
102000044890 human EPO Human genes 0.000 description 2
229920001600 hydrophobic polymer Polymers 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
229910052742 iron Inorganic materials 0.000 description 2
239000007788 liquid Substances 0.000 description 2
238000012792 lyophilization process Methods 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
238000012545 processing Methods 0.000 description 2
239000007790 solid phase Substances 0.000 description 2
239000002904 solvent Substances 0.000 description 2
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
229920000858 Cyclodextrin Polymers 0.000 description 1
SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
238000001159 Fisher's combined probability test Methods 0.000 description 1
102000001554 Hemoglobins Human genes 0.000 description 1
108010054147 Hemoglobins Proteins 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
238000013019 agitation Methods 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
239000012620 biological material Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000002798 bone marrow cell Anatomy 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000013626 chemical specie Substances 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
239000002577 cryoprotective agent Substances 0.000 description 1
229940097362 cyclodextrins Drugs 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
229910001873 dinitrogen Inorganic materials 0.000 description 1
230000000694 effects Effects 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
235000013861 fat-free Nutrition 0.000 description 1
230000008014 freezing Effects 0.000 description 1
238000007710 freezing Methods 0.000 description 1
239000007789 gas Substances 0.000 description 1
239000007943 implant Substances 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
239000008176 lyophilized powder Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
244000005700 microbiome Species 0.000 description 1
239000004005 microsphere Substances 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
230000002572 peristaltic effect Effects 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
239000012071 phase Substances 0.000 description 1
229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
238000005086 pumping Methods 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
210000001995 reticulocyte Anatomy 0.000 description 1
239000012488 sample solution Substances 0.000 description 1
238000013341 scale-up Methods 0.000 description 1
230000007017 scission Effects 0.000 description 1
238000005201 scrubbing Methods 0.000 description 1
238000000926 separation method Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
238000013112 stability test Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
238000003860 storage Methods 0.000 description 1
238000000859 sublimation Methods 0.000 description 1
230000008022 sublimation Effects 0.000 description 1
239000000758 substrate Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
238000012546 transfer Methods 0.000 description 1
239000003656 tris buffered saline Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Zoology (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
Gastroenterology & Hepatology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Vaporization, Distillation, Condensation, Sublimation, And Cold Traps (AREA)

NO19972725A 1994-12-16 1997-06-13 Fremgangsmate for fremstilling av spraytorket rhEPO, samt torr rhEPO fremsatt i henhold til denne metoden og sammensetning derav. NO319895B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US35794794A	1994-12-16	1994-12-16
PCT/US1995/016416 WO1996018647A1 (fr)	1994-12-16	1995-12-15	Erythropoietine sechee par pulverisation

Publications (3)

Publication Number	Publication Date
NO972725D0 NO972725D0 (no)	1997-06-13
NO972725L NO972725L (no)	1997-08-06
NO319895B1 true NO319895B1 (no)	2005-09-26

Family

ID=23407689

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19972725A NO319895B1 (no)	1994-12-16	1997-06-13	Fremgangsmate for fremstilling av spraytorket rhEPO, samt torr rhEPO fremsatt i henhold til denne metoden og sammensetning derav.

Country Status (19)

Country	Link
US (2)	US6001800A (fr)
EP (1)	EP0805822B2 (fr)
JP (1)	JP4039686B2 (fr)
CN (1)	CN1117762C (fr)
AT (1)	ATE265468T1 (fr)
AU (1)	AU697287B2 (fr)
CA (1)	CA2207615C (fr)
DE (1)	DE69532970T3 (fr)
DK (1)	DK0805822T4 (fr)
ES (1)	ES2219672T5 (fr)
FI (1)	FI119723B (fr)
HU (1)	HU222370B1 (fr)
IL (1)	IL116085A (fr)
NO (1)	NO319895B1 (fr)
NZ (1)	NZ298981A (fr)
PT (1)	PT805822E (fr)
TW (1)	TW425287B (fr)
WO (1)	WO1996018647A1 (fr)
ZA (1)	ZA9510708B (fr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19539574A1 (de)	1995-10-25	1997-04-30	Boehringer Mannheim Gmbh	Zubereitungen und Verfahren zur Stabilisierung biologischer Materialien mittels Trocknungsverfahren ohne Einfrieren
US6542481B2 (en)	1998-06-01	2003-04-01	Tantivy Communications, Inc.	Dynamic bandwidth allocation for multiple access communication using session queues
US6081536A (en)	1997-06-20	2000-06-27	Tantivy Communications, Inc.	Dynamic bandwidth allocation to transmit a wireless protocol across a code division multiple access (CDMA) radio link
US6151332A (en)	1997-06-20	2000-11-21	Tantivy Communications, Inc.	Protocol conversion and bandwidth reduction technique providing multiple nB+D ISDN basic rate interface links over a wireless code division multiple access communication system
EP0913177A1 (fr) *	1997-11-03	1999-05-06	Roche Diagnostics GmbH	Procédé pour produire des produits amorphe, sec comprenant de la matière biologique active par séchage convectif, spécialement söchage par pulvérisation
US9525923B2 (en)	1997-12-17	2016-12-20	Intel Corporation	Multi-detection of heartbeat to reduce error probability
US6222832B1 (en)	1998-06-01	2001-04-24	Tantivy Communications, Inc.	Fast Acquisition of traffic channels for a highly variable data rate reverse link of a CDMA wireless communication system
US7394791B2 (en)	1997-12-17	2008-07-01	Interdigital Technology Corporation	Multi-detection of heartbeat to reduce error probability
US7936728B2 (en)	1997-12-17	2011-05-03	Tantivy Communications, Inc.	System and method for maintaining timing of synchronization messages over a reverse link of a CDMA wireless communication system
US7496072B2 (en)	1997-12-17	2009-02-24	Interdigital Technology Corporation	System and method for controlling signal strength over a reverse link of a CDMA wireless communication system
US8175120B2 (en)	2000-02-07	2012-05-08	Ipr Licensing, Inc.	Minimal maintenance link to support synchronization
US7773566B2 (en)	1998-06-01	2010-08-10	Tantivy Communications, Inc.	System and method for maintaining timing of synchronization messages over a reverse link of a CDMA wireless communication system
US8134980B2 (en)	1998-06-01	2012-03-13	Ipr Licensing, Inc.	Transmittal of heartbeat signal at a lower level than heartbeat request
US6526034B1 (en)	1999-09-21	2003-02-25	Tantivy Communications, Inc.	Dual mode subscriber unit for short range, high rate and long range, lower rate data communications
US8155096B1 (en)	2000-12-01	2012-04-10	Ipr Licensing Inc.	Antenna control system and method
US7551663B1 (en)	2001-02-01	2009-06-23	Ipr Licensing, Inc.	Use of correlation combination to achieve channel detection
US6954448B2 (en)	2001-02-01	2005-10-11	Ipr Licensing, Inc.	Alternate channel for carrying selected message types
KR100896971B1 (ko) *	2001-02-02	2009-05-14	오르토-맥네일 파마슈티칼, 인코퍼레이티드	프락토피라노오스 설파메이트 및 에리트로포이에틴을포함하는 신경계 기능장애 치료법
EP2479905B1 (fr)	2001-06-13	2017-03-15	Intel Corporation	Procédé et appareils pour la transmission de signal de pulsation à un niveau inferieur à celui d'une demande de signal de pulsation
WO2004022593A2 (fr) *	2002-09-09	2004-03-18	Nautilus Biotech	Evolution rationnelle de cytokines pour une plus grande stabilite, les cytokines et molecules d'acide nucleique codant
US20050053666A1 (en) *	2002-12-31	2005-03-10	Stelios Tzannis	Antibody-containing particles and compositions
JP4745826B2 (ja)	2003-11-14	2011-08-10	中外製薬株式会社	架橋多糖微粒子およびその製造方法
CN104803865A (zh)	2004-12-22	2015-07-29	Ambrx公司	含有非天然氨基酸和多肽的组合物、涉及非天然氨基酸和多肽的方法以及其用途
EP1836314B1 (fr)	2004-12-22	2012-01-25	Ambrx, Inc.	Hormone de croissance humaine modifiee
CN101454461A (zh)	2005-11-16	2009-06-10	Ambrx公司	包括非天然氨基酸的方法和组合物
WO2008030558A2 (fr)	2006-09-08	2008-03-13	Ambrx, Inc.	Polypeptide plasmatique humain modifié ou squelettes de fc et leurs utilisations
KR101248252B1 (ko)	2006-11-28	2013-03-27	한올바이오파마주식회사	변형된 에리스로포이에틴 폴리펩티드와 이의 치료용 용도
ES2385114T3 (es)	2007-03-30	2012-07-18	Ambrx, Inc.	Polipéptidos de FGF-21 modificados y sus usos
NZ580686A (en)	2007-05-02	2012-11-30	Ambrx Inc	Modified interferon beta polypeptides and their uses
NZ601913A (en)	2008-01-15	2014-02-28	Abbott Gmbh & Co Kg	Powdered protein compositions and methods of making same
CN106928339A (zh)	2008-07-23	2017-07-07	Ambrx 公司	经修饰的牛g‑csf多肽和其用途
PT104350A (pt) *	2009-01-23	2010-07-23	Hovione Farmaci Ncia S A	Processo de isolamento de tigeciclina
EP2805964A1 (fr)	2009-12-21	2014-11-26	Ambrx, Inc.	Polypeptides modifiés de somatotrophine bovine et leurs utilisations
MX2012006980A (es)	2009-12-21	2012-07-17	Ambrx Inc	Polipeptidos de somatotropina porcina modificados y sus usos.
AR083006A1 (es)	2010-09-23	2013-01-23	Lilly Co Eli	Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
TW201309346A (zh)	2011-01-05	2013-03-01	Hospira Inc	噴霧乾燥萬古黴素
WO2013126552A1 (fr)	2012-02-21	2013-08-29	Auburn University	Composition de nanoparticules de buprénorphine et procédés correspondants
CN104043104B (zh)	2013-03-15	2018-07-10	浙江创新生物有限公司	含盐酸万古霉素的喷雾干粉及其工业化制备方法
EP3209316A2 (fr)	2014-10-24	2017-08-30	Bristol-Myers Squibb Company	Polypeptides fgf-21 modifiés et leurs utilisations
CN104984323B (zh) *	2015-06-12	2018-05-01	北京四环生物制药有限公司	注射用重组人促红素冻干粉针剂
CN105311624A (zh) *	2015-11-23	2016-02-10	哈药集团生物工程有限公司	一种含有重组人促红素的药物组合物
CN116948006A (zh)	2018-09-11	2023-10-27	北京泰德制药股份有限公司	白介素-2多肽偶联物及其用途
US20220009986A1 (en)	2018-10-19	2022-01-13	Ambrx, Inc.	Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
US20220226488A1 (en)	2019-02-12	2022-07-21	Ambrx, Inc.	Compositions containing, methods and uses of antibody-tlr agonist conjugates
CA3174114A1 (fr)	2020-03-11	2021-09-16	Ambrx, Inc.	Conjugues polypeptidiques d'interleukine-2 et leurs procedes d'utilisation
TW202227449A (zh)	2020-08-20	2022-07-16	美商Ａｍｂｒｘ公司	抗體－ｔｌｒ促效劑偶聯物、其方法及用途
CA3213805A1 (fr)	2021-04-03	2022-10-06	Feng Tian	Conjugues anticorps-medicament anti-her2 et leurs utilisations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS57149228A (en) *	1981-03-11	1982-09-14	Ajinomoto Co Inc	Novel erythropoietin and its preparation
JPS6197229A (ja) *	1984-10-18	1986-05-15	Chugai Pharmaceut Co Ltd	安定なエリトロポエチン製剤
DE3729863A1 (de) *	1987-09-05	1989-03-16	Boehringer Mannheim Gmbh	Stabilisierte erythropoietin-lyophilisate
GB9001987D0 (en) *	1990-01-29	1990-03-28	Janssen Pharmaceutica Nv	Improved cyclodextrin based erythropietin formulation
US5354934A (en) *	1993-02-04	1994-10-11	Amgen Inc.	Pulmonary administration of erythropoietin

1995
- 1995-11-21 IL IL11608595A patent/IL116085A/xx not_active IP Right Cessation
- 1995-12-15 PT PT95943452T patent/PT805822E/pt unknown
- 1995-12-15 ES ES95943452T patent/ES2219672T5/es not_active Expired - Lifetime
- 1995-12-15 CN CN95197638.9A patent/CN1117762C/zh not_active Expired - Lifetime
- 1995-12-15 ZA ZA9510708A patent/ZA9510708B/xx unknown
- 1995-12-15 DE DE69532970T patent/DE69532970T3/de not_active Expired - Lifetime
- 1995-12-15 JP JP51929496A patent/JP4039686B2/ja not_active Expired - Lifetime
- 1995-12-15 DK DK95943452.3T patent/DK0805822T4/da active
- 1995-12-15 EP EP95943452A patent/EP0805822B2/fr not_active Expired - Lifetime
- 1995-12-15 AT AT95943452T patent/ATE265468T1/de active
- 1995-12-15 HU HU9800996A patent/HU222370B1/hu active IP Right Grant
- 1995-12-15 CA CA2207615A patent/CA2207615C/fr not_active Expired - Lifetime
- 1995-12-15 WO PCT/US1995/016416 patent/WO1996018647A1/fr active IP Right Grant
- 1995-12-15 NZ NZ298981A patent/NZ298981A/xx not_active IP Right Cessation
- 1995-12-15 AU AU44713/96A patent/AU697287B2/en not_active Expired
1996
- 1996-06-06 TW TW085106816A patent/TW425287B/zh not_active IP Right Cessation
- 1996-12-15 US US08/894,023 patent/US6001800A/en not_active Expired - Lifetime
1997
- 1997-06-13 NO NO19972725A patent/NO319895B1/no not_active IP Right Cessation
- 1997-06-16 FI FI972557A patent/FI119723B/fi not_active IP Right Cessation
1999
- 1999-10-12 US US09/415,726 patent/US6235710B1/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
FI972557A0 (fi)	1997-06-16
NO972725D0 (no)	1997-06-13
CA2207615A1 (fr)	1996-06-20
CN1175261A (zh)	1998-03-04
AU4471396A (en)	1996-07-03
MX9704504A (es)	1998-06-30
IL116085A (en)	1999-12-31
JPH10511087A (ja)	1998-10-27
US6235710B1 (en)	2001-05-22
CA2207615C (fr)	2010-12-14
DK0805822T3 (da)	2004-08-16
ATE265468T1 (de)	2004-05-15
NO972725L (no)	1997-08-06
FI972557A (fi)	1997-08-14
EP0805822B2 (fr)	2011-06-15
EP0805822A1 (fr)	1997-11-12
IL116085A0 (en)	1996-01-31
ES2219672T3 (es)	2004-12-01
DE69532970T3 (de)	2012-02-09
US6001800A (en)	1999-12-14
HU222370B1 (hu)	2003-06-28
FI119723B (fi)	2009-02-27
ES2219672T5 (es)	2011-09-26
AU697287B2 (en)	1998-10-01
WO1996018647A1 (fr)	1996-06-20
DE69532970D1 (en)	2004-06-03
HUT77811A (hu)	1998-08-28
PT805822E (pt)	2004-08-31
NZ298981A (en)	1999-11-29
ZA9510708B (en)	1997-06-17
EP0805822B1 (fr)	2004-04-28
JP4039686B2 (ja)	2008-01-30
TW425287B (en)	2001-03-11
DK0805822T4 (da)	2011-07-11
CN1117762C (zh)	2003-08-13
DE69532970T2 (de)	2005-06-09

Legal Events

Date	Code	Title	Description
2015-12-28	MK1K	Patent expired

Publication	Publication Date	Title
NO319895B1 (no)	2005-09-26	Fremgangsmate for fremstilling av spraytorket rhEPO, samt torr rhEPO fremsatt i henhold til denne metoden og sammensetning derav.
Izutsu et al.	1993	Decreased protein-stabilizing effects of cryoprotectants due to crystallization
Mumenthaler et al.	1994	Feasibility study on spray-drying protein pharmaceuticals: recombinant human growth hormone and tissue-type plasminogen activator
Lee	2002	Spray-drying of proteins
CA2336376C (fr)	2008-11-25	Formulation a microparticules pour inhalation
EP1932519B1 (fr)	2013-02-20	Formules de stabilisation de protéine
US6451349B1 (en)	2002-09-17	Spray-drying process for the preparation of microparticles
Österberg et al.	1997	Development of a freeze-dried albumin-free formulation of recombinant factor VIII SQ
JPH08507064A (ja)	1996-07-30	有機溶媒を用いて処理したポリペプチドの賦形剤安定化
KR100705997B1 (ko)	2007-07-09	안정화된 hgf 동결건조제제 및 그 제조방법
NO316661B1 (no)	2004-03-22	Fremgangsmate for forstovning av en insulindose og et insulinprodukt
KR100461291B1 (ko)	2005-02-28	건조조성물
CA2234724A1 (fr)	1997-04-24	Formes galeniques pharmaceutiques stables contenant de la parathormone
JPH05331071A (ja)	1993-12-14	カルシトニン遺伝子関連ペプチド類の凍結乾燥組成物および安定化法
JPH04208228A (ja)	1992-07-29	インシュリン様成長因子ｉの乾燥製剤
MXPA97004504A (en)	1998-10-30	Aspected eritropoyetin
Jones et al.	1995	New delivery systems for recombinant proteins—practical issues from proof of concept to clinic
JP2001151694A (ja)	2001-06-05	タンパク質粉体の製造法
MXPA01000105A (en)	2002-07-25	Microparticle formulation for inhalation
MXPA00012652A (en)	2001-07-31	Improved process for preparing schiff base adducts of amines with o